We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Vedolizumab Dose Escalation: In for a Penny, in for a Pound?
- Authors
Dart, Robin J.; Irving, Peter M.; Samaan, Mark A.
- Abstract
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. 2 Peyrin-Biroulet L, Danese S, Argollo M. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis. Regarding the choices of biologic agents for IBD, as is for all therapeutic interventions, it is often said that the most expensive drug is the one that fails to work.
- Subjects
VEDOLIZUMAB; INFLAMMATORY bowel diseases; CROHN'S disease
- Publication
Digestive Diseases & Sciences, 2021, Vol 66, Issue 6, p1772
- ISSN
0163-2116
- Publication type
editorial
- DOI
10.1007/s10620-020-06565-z